The mechanisms underlying chemically-mediated malignant transformation are to be explored. Model systems to be used include in vivo exposure of rodents to thioacetamide, ethionine, alkylnitrosamines, and amino azo dyes. In vitro exposure of hepatocyte cultures to these same agents will also be employed. Previous data show a modification of nuclear restriction of RNA species in liver cells exposed to carcinogens, potentially representing an initiating or a promoting event, or both. The major areas to be investigated include: (1) an analysis of the cell-free model of nuclear RNA transport to determine the role of high-energy bond hydrolysis as a driving force, and to assay for the significance of both selection of RNA species for secretion and for back-diffusion to the nucleus; (2) an analysis of in vivo restriction in the two-stage model of hepatocarcinogenesis to learn whether """"""""nuclear leakage"""""""" is related to initiation or to promotion; (3) the fidelity of the in vitro system will be surveyed. Specific cDNA probes for messenger species (Alpha1-glycoprotein and AlphaMu-globulin) will be used to measure messenger release in vivo and compare these data to in vitro release following turpentine and androgenic stimulation of male rats. Additionally, these cDNA probes will be used to isolate the messengers in vivo and in vitro to compare splicing, processing, and polyadenylation following the release in vivo and in vitro; 4) an attempt wil be made to purify and characterize the nuclear matrix and nuclear envelope NTase and to define their role in transport. The potential that these also represent an ATP driven endonuclease will be tested. This point seems relevant to the apparent frequency of genetic information relocation associated with oncogene expression. These experiments will be used to test the hypothesis that malignant transformation involves alterations in the transcription and processing of RNA, at least as a basis for the phenotypic expression of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA021141-12
Application #
3165469
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1987-04-01
Project End
1987-12-31
Budget Start
1987-04-01
Budget End
1987-12-31
Support Year
12
Fiscal Year
1987
Total Cost
Indirect Cost
Name
George Washington University
Department
Type
Schools of Medicine
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20052
Crone, T M; Schalles, S L; Benedict, C M et al. (1999) Growth inhibition by a triple ribozyme targeted to repetitive B2 transcripts. Hepatology 29:1114-23
Weisz, J; Clawson, G A; Creveling, C R (1998) Biogenesis and inactivation of catecholestrogens. Adv Pharmacol 42:828-33
Weisz, J; Fritz-Wolz, G; Clawson, G A et al. (1998) Induction of nuclear catechol-O-methyltransferase by estrogens in hamster kidney: implications for estrogen-induced renal cancer. Carcinogenesis 19:1307-12
Benedict, C M; Pan, W; Loy, S E et al. (1998) Triple ribozyme-mediated down-regulation of the retinoblastoma gene. Carcinogenesis 19:1223-30
Clawson, G A; Benedict, C M; Kelley, M R et al. (1997) Focal nuclear hepatocyte response to oxidative damage following low dose thioacetamide intoxication. Carcinogenesis 18:1663-8
Ren, L; Clawson, G A (1997) Studies on rLMP7, a beta-subunit of the multicatalytic proteinase. Exp Cell Res 234:105-14
Clawson, G A; Schalles, S L; Wolz, G et al. (1996) Focal altered compartmentation of repetitive B2 (Alu-like) sequences in rat liver following hepatocarcinogen exposure. Cell Growth Differ 7:635-46
Clawson, G A (1996) Protease inhibitors and carcinogenesis: a review. Cancer Invest 14:597-608
Benedict, C M; Clawson, G A (1996) Nuclear multicatalytic proteinase subunit RRC3 is important for growth regulation in hepatocytes. Biochemistry 35:11612-21
Clawson, G A; Ren, L; Isom, H C (1995) Nuclear scaffold-associated protease: in situ nuclear localization and effects of a protease inhibitor on growth and morphology of a ras-transformed hepatocyte cell line. Hepatology 22:1230-5

Showing the most recent 10 out of 38 publications